- Home
- NBB vs FTRE Comparison
NBB vs FTRE Comparison
Compare NBB & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBB
- FTRE
- Stock Information
- Founded
- NBB 2009
- FTRE 1996
- Country
- NBB United States
- FTRE United States
- Employees
- NBB N/A
- FTRE N/A
- Industry
- NBB Finance Companies
- FTRE Medical Specialities
- Sector
- NBB Finance
- FTRE Health Care
- Exchange
- NBB Nasdaq
- FTRE Nasdaq
- Market Cap
- NBB 462.1M
- FTRE 468.1M
- IPO Year
- NBB N/A
- FTRE N/A
- Fundamental
- Price
- NBB $15.66
- FTRE $5.12
- Analyst Decision
- NBB
- FTRE Hold
- Analyst Count
- NBB 0
- FTRE 11
- Target Price
- NBB N/A
- FTRE $16.00
- AVG Volume (30 Days)
- NBB 73.9K
- FTRE 2.8M
- Earning Date
- NBB 01-01-0001
- FTRE 08-11-2025
- Dividend Yield
- NBB 8.64%
- FTRE N/A
- EPS Growth
- NBB N/A
- FTRE N/A
- EPS
- NBB N/A
- FTRE N/A
- Revenue
- NBB N/A
- FTRE $2,685,600,000.00
- Revenue This Year
- NBB N/A
- FTRE N/A
- Revenue Next Year
- NBB N/A
- FTRE $0.93
- P/E Ratio
- NBB N/A
- FTRE N/A
- Revenue Growth
- NBB N/A
- FTRE N/A
- 52 Week Low
- NBB $13.67
- FTRE $3.97
- 52 Week High
- NBB $16.66
- FTRE $28.41
- Technical
- Relative Strength Index (RSI)
- NBB 50.83
- FTRE 49.47
- Support Level
- NBB $15.62
- FTRE $4.36
- Resistance Level
- NBB $15.91
- FTRE $5.61
- Average True Range (ATR)
- NBB 0.20
- FTRE 0.39
- MACD
- NBB -0.00
- FTRE -0.00
- Stochastic Oscillator
- NBB 55.36
- FTRE 60.00
About NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest
Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests primarily in a diversified portfolio of taxable municipal securities.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.